Clinical Trial Update: Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of imatinib and carvedilol for pulmonary hypertension in adults with sickle cell disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Sickle Cell Disease

Drugs mentioned

• Coreg (carvedilol)
• Gleevec (Imatinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Pulmonary Hypertension | Phase 1 | Status: WITHDRAWN